Shahneen Sandhu - Concepedia

Author

Shahneen Sandhu

Also Known As

David Pook, Douglas S Tyler, K. K. Sandhu, L Lancerotto, MURAL investigators, Paul Neeson, R Maamari, Rachel Delahunty, S Sandhu, S. K. Sandhu

642

Publications

34.6K

Citations

H-Index

127

Concepts

All Affiliations

Peter MacCallum Cancer Centre The University of Melbourne The University of Sydney Melanoma Institute Australia Monash University

About

Shahneen Sandhu is an author at Peter MacCallum Cancer Centre specializing in medicine, oncology, and cancer therapeutics.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Medicine	52	113	13.2K
2	Health Sciences	17	22	1.2K
3	Engineering	2	2	358
4	Education	1	1	38
5	Nursing	1	1	38

Shahneen Sandhu

218

Publications

29.6K

Citations

H-Index

Page 1

	Year	Citations
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer Joaquı́n Mateo, Suzanne Carreira, Shahneen Sandhu, New England Journal of Medicine	2015	2.1K
Olaparib for Metastatic Castration-Resistant Prostate Cancer Johann S. de Bono, Joaquı́n Mateo, Karim Fizazi, New England Journal of Medicine	2020	2.1K
Adjuvant Pembrolizumab versus Placebo in Resected Stage III Melanoma Alexander M.M. Eggermont, Christian U. Blank, Mario Mandalà, New England Journal of Medicine	2018	1.8K
Enzalutamide with Standard First-Line Therapy in Metastatic Prostate Cancer Ian D. Davis, Andrew Martin, Martin R. Stockler, New England Journal of Medicine	2019	1.5K
[177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study Michael S. Hofman, John Violet, Rodney J. Hicks, The Lancet Oncology	2018	1.1K
[177Lu]Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial Michael S. Hofman, Louise Emmett, Shahneen Sandhu, The Lancet UrologyOncologyGenitourinary CancerMedicineClinical Trials	2021	1K
Combination nivolumab and ipilimumab or nivolumab alone in melanoma brain metastases: a multicentre randomised phase 2 study Georgina V. Long, Victoria Atkinson, Serigne Lo, The Lancet Oncology Neuro-oncologyMelanoma Brain MetastasesMedicineMelanomaPathology	2018	975
Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab Alexander M. Menzies, Douglas B. Johnson, Sangeetha Ramanujam, Annals of Oncology Autoimmune DisordersAutoimmune DiseaseAnti-pd-1 TherapyMelanomaImmunology	2016	811
Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer Maha Hussain, Joaquı́n Mateo, Karim Fizazi, New England Journal of Medicine	2020	734
Olaparib in patients with metastatic castration-resistant prostate cancer with DNA repair gene aberrations (TOPARP-B): a multicentre, open-label, randomised, phase 2 trial Joaquı́n Mateo, Núria Porta, Diletta Bianchini, The Lancet Oncology	2019	632

Page 1